Professional development - Membership of the RCGP
Dr Sathya Naidoo explains the criteria that are required for completing iMAP. Read more
The UK National Screening Committee (NSC) has released guidance on how CVD screening would operate.
For an average practice of 6,000 patients, this would result in 140 half-an-hour screening sessions per year, equivalent to three to four per week.
The NSC's latest report says a population-wide screening programme is feasible, ‘even in the most deprived inner-city practices'.
The evidence recommends conducting a vascular risk assessment on all patients aged 40-74, every five years.
The NSC calculates that the average practice would diagnose four new cases of diabetes mellitus and 17 new diagnoses of impaired glucose regulation per year.
Mr Brown suggested in January that screening for CVD, diabetes, chronic kidney disease, stroke risk and chronic lung diseases would become available to anyone.
A DoH spokeswoman said economic modelling work to look at the feasibility of vascular risk screening is underway.
But Professor Richard Hobbs, chairman of the Primary Care Cardiovascular Society, said: ‘It would be more appropriate to get a high-risk screening programme off the ground first, and then see if a national programme could be cost-effective.'
GPC deputy chairman Dr Richard Vautrey said CVD screening would require a significant increase in GP workload and resources.
tom.ireland@haymarket.com
Comment below and tell us what you think
Dr Sathya Naidoo explains the criteria that are required for completing iMAP. Read more
Applying to the RCGP for your CCT recommendation now takes three clicks, writes Fiona Erasmus. Read more
Medicolegal advisor, Dr John Holden addresses some dilemmas on consent that may be faced by GPs. Read more
Section 1 Definition and pathophysiology Read more
Contributed by Mr Michael Booker, consultant obstetrician & gynaecologist, and fertility specialist ... Read more
Contributed by Mr David Scott-Coombes, consultant endocrine surgeon at the University Hospital of Wa... Read more
Pfizer has launched Toviaz (fesoterodine), a once-daily treatment for the symptoms of overactive bla... Read more
Novartis has launched Tasigna (nilotinib), a new antineoplastic agent for Philadelphia chromosome po... Read more
The licence for Ciproxin (ciprofloxacin) has been extended to include the second- and third-line tr... Read more
Comments
Only registered users may comment. Log in now or register for a free account.